1. Home
  2. MLAB vs DBVT Comparison

MLAB vs DBVT Comparison

Compare MLAB & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MLAB
  • DBVT
  • Stock Information
  • Founded
  • MLAB 1982
  • DBVT 2002
  • Country
  • MLAB United States
  • DBVT France
  • Employees
  • MLAB N/A
  • DBVT N/A
  • Industry
  • MLAB Industrial Machinery/Components
  • DBVT Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • MLAB Industrials
  • DBVT Health Care
  • Exchange
  • MLAB Nasdaq
  • DBVT Nasdaq
  • Market Cap
  • MLAB 441.2M
  • DBVT 464.0M
  • IPO Year
  • MLAB N/A
  • DBVT N/A
  • Fundamental
  • Price
  • MLAB $73.67
  • DBVT $13.57
  • Analyst Decision
  • MLAB Hold
  • DBVT Buy
  • Analyst Count
  • MLAB 1
  • DBVT 5
  • Target Price
  • MLAB $67.00
  • DBVT $15.85
  • AVG Volume (30 Days)
  • MLAB 100.5K
  • DBVT 122.3K
  • Earning Date
  • MLAB 11-06-2025
  • DBVT 10-28-2025
  • Dividend Yield
  • MLAB 0.87%
  • DBVT N/A
  • EPS Growth
  • MLAB N/A
  • DBVT N/A
  • EPS
  • MLAB N/A
  • DBVT N/A
  • Revenue
  • MLAB $245,255,000.00
  • DBVT $5,502,000.00
  • Revenue This Year
  • MLAB $5.38
  • DBVT $1,743.46
  • Revenue Next Year
  • MLAB $5.25
  • DBVT $1,045.66
  • P/E Ratio
  • MLAB N/A
  • DBVT N/A
  • Revenue Growth
  • MLAB 7.39
  • DBVT N/A
  • 52 Week Low
  • MLAB $55.45
  • DBVT $2.21
  • 52 Week High
  • MLAB $155.12
  • DBVT $18.00
  • Technical
  • Relative Strength Index (RSI)
  • MLAB 46.86
  • DBVT 44.71
  • Support Level
  • MLAB $70.00
  • DBVT $12.56
  • Resistance Level
  • MLAB $82.37
  • DBVT $14.71
  • Average True Range (ATR)
  • MLAB 4.39
  • DBVT 1.18
  • MACD
  • MLAB -0.25
  • DBVT -0.32
  • Stochastic Oscillator
  • MLAB 29.18
  • DBVT 19.30

About MLAB Mesa Laboratories Inc.

Mesa Laboratories Inc manufactures life sciences tools and critical quality control products. It operates in four divisions: Sterilization and Disinfection Control, which manufactures and sells biological, chemical, and cleaning indicators used to assess the effectiveness of sterilization, decontamination, disinfection, and cleaning processes. Clinical Genomics division develops, manufactures, and sells highly sensitive, low-cost, high-throughput genetic analysis tools and related consumables. The Biopharmaceutical Development division develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. The Calibration Solutions division develops, manufactures, sells, and services quality control products.

About DBVT DBV Technologies S.A.

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.

Share on Social Networks: